NCI-60 Molecular Targets
http://dtp.cancer.gov/mtargets/mt_index.html

1.	Wang, F. E., Zhang, C., Maminishkis, A., Dong, L., Zhi, C., Li, R., Zhao, J., Majerciak, V., Gaur, A. B., Chen, S. & Miller, S. S. (2010). MicroRNA-204/211 alters epithelial physiology. FASEB J 24, 1552-71.
2.	Vazquez, A., Grochola, L. F., Bond, E. E., Levine, A. J., Taubert, H., Muller, T. H., Wurl, P. & Bond, G. L. (2010). Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res 70, 172-80.
3.	Stuelten, C. H., Mertins, S. D., Busch, J. I., Gowens, M., Scudiero, D. A., Burkett, M. W., Hite, K. M., Alley, M., Hollingshead, M., Shoemaker, R. H. & Niederhuber, J. E. (2010). Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28, 649-60.
4.	Park, E. S., Rabinovsky, R., Carey, M., Hennessy, B. T., Agarwal, R., Liu, W., Ju, Z., Deng, W., Lu, Y., Woo, H. G., Kim, S. B., Cheong, J. H., Garraway, L. A., Weinstein, J. N., Mills, G. B., Lee, J. S. & Davies, M. A. (2010). Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9, 257-67.
5.	Holbeck, S., Chang, J., Best, A. M., Bookout, A. L., Mangelsdorf, D. J. & Martinez, E. D. (2010). Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Mol Endocrinol 24, 1287-96.
6.	Franke, R. M., Kosloske, A. M., Lancaster, C. S., Filipski, K., Hu, C., Zolk, O., Mathijssen, R. H. & Sparreboom, A. (2010). Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-{beta}-D-Glucosaminidase. Clin Cancer Res.
7.	Nissen, K. K., Vogel, U. & Nexo, B. A. (2009). Association of a single nucleotide polymorphic variation in the human chromosome 19q13.3 with drug responses in the NCI60 cell lines. Anticancer Drugs 20, 174-8.
8.	Stoeger, S. M. & Cowan, K. H. (2008). Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines. Cancer Chemother Pharmacol.
9.	Ehrich, M., Turner, J., Gibbs, P., Lipton, L., Giovanneti, M., Cantor, C. & van den Boom, D. (2008). Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci U S A 105, 4844-9.
10.	Blower, P. E., Chung, J. H., Verducci, J. S., Lin, S., Park, J. K., Dai, Z., Liu, C. G., Schmittgen, T. D., Reinhold, W. C., Croce, C. M., Weinstein, J. N. & Sadee, W. (2008). MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7, 1-9.
11.	Suh, K. S., Crutchley, J. M., Koochek, A., Ryscavage, A., Bhat, K., Tanaka, T., Oshima, A., Fitzgerald, P. & Yuspa, S. H. (2007). Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers. Clin Cancer Res 13, 121-31.
12.	Shell, S., Park, S. M., Radjabi, A. R., Schickel, R., Kistner, E. O., Jewell, D. A., Feig, C., Lengyel, E. & Peter, M. E. (2007). Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 104, 11400-5.
13.	Reinhold, W. C., Reimers, M. A., Maunakea, A. K., Kim, S., Lababidi, S., Scherf, U., Shankavaram, U. T., Ziegler, M. S., Stewart, C., Kouros-Mehr, H., Cui, H., Dolginow, D., Scudiero, D. A., Pommier, Y. G., Munroe, D. J., Feinberg, A. P. & Weinstein, J. N. (2007). Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther 6, 391-403.
14.	Park, S. M., Shell, S., Radjabi, A. R., Schickel, R., Feig, C., Boyerinas, B., Dinulescu, D. M., Lengyel, E. & Peter, M. E. (2007). Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6, 2585-90.
15.	Liu, W., Wu, X., Zhang, W., Montenegro, R. C., Fackenthal, D. L., Spitz, J. A., Huff, L. M., Innocenti, F., Das, S., Cook, E. H., Jr., Cox, N. J., Bates, S. E. & Ratain, M. J. (2007). Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13, 6788-95.
16.	Gaur, A., Jewell, D. A., Liang, Y., Ridzon, D., Moore, J. H., Chen, C., Ambros, V. R. & Israel, M. A. (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67, 2456-68.
17.	Carrick, D. M. & Blackshear, P. J. (2007). Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch Biochem Biophys 462, 278-85.
18.	Blower, P. E., Verducci, J. S., Lin, S., Zhou, J., Chung, J. H., Dai, Z., Liu, C. G., Reinhold, W., Lorenzi, P. L., Kaldjian, E. P., Croce, C. M., Weinstein, J. N. & Sadee, W. (2007). MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6, 1483-91.
19.	Whyte, D. B. & Holbeck, S. L. (2006). Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 340, 469-75.
20.	Paulsen, M. T., Starks, A. M., Derheimer, F. A., Hanasoge, S., Li, L., Dixon, J. E. & Ljungman, M. (2006). The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers. Mol Cancer 5, 25.
21.	Moisan, F., Longy, M., Robert, J. & Le Morvan, V. (2006). Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. Br J Cancer 95, 906-13.
22.	Loegering, D. A., Ruchaud, S., Earnshaw, W. C. & Kaufmann, S. H. (2006). Evaluation of the role of caspase-6 in anticancer drug-induced apoptosis. Cell Death Differ 13, 346-7.
23.	Le Morvan, V., Bellott, R., Moisan, F., Mathoulin-Pelissier, S., Bonnet, J. & Robert, J. (2006). Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-a-vis the NCI-60 panel. Pharmacogenomics 7, 843-852.
24.	Kolonin, M. G., Bover, L., Sun, J., Zurita, A. J., Do, K. A., Lahdenranta, J., Cardo-Vila, M., Giordano, R. J., Jaalouk, D. E., Ozawa, M. G., Moya, C. A., Souza, G. R., Staquicini, F. I., Kunyiasu, A., Scudiero, D. A., Holbeck, S. L., Sausville, E. A., Arap, W. & Pasqualini, R. (2006). Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 66, 34-40.
25.	Ikediobi, O. N., Davies, H., Bignell, G., Edkins, S., Stevens, C., O'Meara, S., Santarius, T., Avis, T., Barthorpe, S., Brackenbury, L., Buck, G., Butler, A., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Hunter, C., Jenkinson, A., Jones, D., Kosmidou, V., Lugg, R., Menzies, A., Mironenko, T., Parker, A., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Smith, R., Solomon, H., Stephens, P., Teague, J., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Reinhold, W., Weinstein, J. N., Stratton, M. R., Futreal, P. A. & Wooster, R. (2006). Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5, 2606-12.
26.	Garraway, L. A. & Sellers, W. R. (2006). From integrated genomics to tumor lineage dependency. Cancer Res 66, 2506-8.
27.	Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P. A. & Stratton, M. R. (2006). Cosmic 2005. Br J Cancer.
28.	Zhang, W., Braun, A., Bauman, Z., Olteanu, H., Madzelan, P. & Banerjee, R. (2005). Expression profiling of homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. Cancer Res 65, 1554-60.
29.	Yarosh, D. B., Pena, A. & Brown, D. A. (2005). DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumour Cell Line Screening Panel. Biomarkers 10, 188-202.
30.	Lin, Y. W., Deveney, R., Barbara, M., Iscove, N. N., Nimer, S. D., Slape, C. & Aplan, P. D. (2005). OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. Cancer Res 65, 7151-8.
31.	Hansen, R. M., Goriely, A., Wall, S. A., Roberts, I. S. & Wilkie, A. O. (2005). Fibroblast growth factor receptor 2, gain-of-function mutations, and tumourigenesis: investigating a potential link. J Pathol 207, 27-31.
32.	Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., Lee, C., Wagner, S. N., Li, C., Golub, T. R., Rimm, D. L., Meyerson, M. L., Fisher, D. E. & Sellers, W. R. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-22.
33.	Garraway, L. A., Weir, B. A., Zhao, X., Widlund, H., Beroukhim, R., Berger, A., Rimm, D., Rubin, M. A., Fisher, D. E., Meyerson, M. L. & Sellers, W. R. (2005). "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harb Symp Quant Biol 70, 25-34.
34.	Adams, S., Robbins, F. M., Chen, D., Wagage, D., Holbeck, S. L., Morse, H. C., 3rd, Stroncek, D. & Marincola, F. M. (2005). HLA class I and II genotype of the NCI-60 cell lines. J Transl Med 3, 11.
35.	Szakacs, G., Annereau, J. P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., Weinstein, J. N. & Gottesman, M. M. (2004). Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6, 129-37.
36.	Svingen, P. A., Loegering, D., Rodriquez, J., Meng, X. W., Mesner, P. W., Jr., Holbeck, S., Monks, A., Krajewski, S., Scudiero, D. A., Sausville, E. A., Reed, J. C., Lazebnik, Y. A. & Kaufmann, S. H. (2004). Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. Clin Cancer Res 10, 6807-20.
37.	Jansen, A. P., Camalier, C. E., Stark, C. & Colburn, N. H. (2004). Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 3, 103-10.
38.	Dick, R. A., Yu, X. & Kensler, T. W. (2004). NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven. Clin Cancer Res 10, 1492-9.
39.	Schnier, J. B., Nishi, K., Monks, A., Gorin, F. A. & Bradbury, E. M. (2003). Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression. Biochem Biophys Res Commun 309, 126-34.
40.	Roschke, A. V., Tonon, G., Gehlhaus, K. S., McTyre, N., Bussey, K. J., Lababidi, S., Scudiero, D. A., Weinstein, J. N. & Kirsch, I. R. (2003). Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63, 8634-47.
41.	Pasquale, G. D., Davidson, B. L., Stein, C. S., Martins, I., Scudiero, D., Monks, A. & Chiorini, J. A. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9, 1306-12.
42.	Nishizuka, S., Chen, S. T., Gwadry, F. G., Alexander, J., Major, S. M., Scherf, U., Reinhold, W. C., Waltham, M., Charboneau, L., Young, L., Bussey, K. J., Kim, S., Lababidi, S., Lee, J. K., Pittaluga, S., Scudiero, D. A., Sausville, E. A., Munson, P. J., Petricoin, E. F., 3rd, Liotta, L. A., Hewitt, S. M., Raffeld, M. & Weinstein, J. N. (2003). Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63, 5243-50.
43.	Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., Munson, P. J., Petricoin, E., 3rd, Liotta, L. A. & Weinstein, J. N. (2003). Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100, 14229-34.
44.	Algeciras-Schimnich, A., Pietras, E. M., Barnhart, B. C., Legembre, P., Vijayan, S., Holbeck, S. L. & Peter, M. E. (2003). Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A 100, 11445-50.
45.	Xu, Z., Chen, Z. P., Malapetsa, A., Alaoui-Jamali, M., Bergeron, J., Monks, A., Myers, T. G., Mohr, G., Sausville, E. A., Scudiero, D. A., Aloyz, R. & Panasci, L. C. (2002). DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13, 511-9.
46.	Scheffer, G. L., de Jong, M. C., Monks, A., Flens, M. J., Hose, C. D., Izquierdo, M. A., Shoemaker, R. H. & Scheper, R. J. (2002). Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells. Br J Cancer 86, 1943-50.
47.	Prades, C., Arnould, I., Annilo, T., Shulenin, S., Chen, Z. Q., Orosco, L., Triunfol, M., Devaud, C., Maintoux-Larois, C., Lafargue, C., Lemoine, C., Denefle, P., Rosier, M. & Dean, M. (2002). The human ATP binding cassette gene ABCA13, located on chromosome 7p12.3, encodes a 5058 amino acid protein with an extracellular domain encoded in part by a 4.8-kb conserved exon. Cytogenet Genome Res 98, 160-8.
48.	Lu, X., Gong, S., Monks, A., Zaharevitz, D. & Moscow, J. A. (2002). Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. J Exp Ther Oncol 2, 200-12.
49.	Krajewska, M., Zapata, J. M., Meinhold-Heerlein, I., Hedayat, H., Monks, A., Bettendorf, H., Shabaik, A., Bubendorf, L., Kallioniemi, O. P., Kim, H., Reifenberger, G., Reed, J. C. & Krajewski, S. (2002). Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4, 129-40.
50.	Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y. & Sugimoto, Y. (2002). C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1, 611-6.
51.	Cosenza, L., Gorgun, G., Urbano, A. & Foss, F. (2002). Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal 14, 317-25.
52.	Yu, L. J., Matias, J., Scudiero, D. A., Hite, K. M., Monks, A., Sausville, E. A. & Waxman, D. J. (2001). P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 29, 304-12.
53.	Vulevic, B., Chen, Z., Boyd, J. T., Davis, W., Jr., Walsh, E. S., Belinsky, M. G. & Tew, K. D. (2001). Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res 61, 3339-47.
54.	Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., Mesirov, J. P., Lander, E. S. & Golub, T. R. (2001). Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 98, 10787-92.
55.	Parr, A. L., Myers, T. G., Holbeck, S. L., Loh, Y. J. & Allegra, C. J. (2001). Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen. Anticancer Drugs 12, 569-74.
56.	Nicoletti, M. I., Valoti, G., Giannakakou, P., Zhan, Z., Kim, J. H., Lucchini, V., Landoni, F., Mayo, J. G., Giavazzi, R. & Fojo, T. (2001). Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 7, 2912-22.
57.	Meinhold-Heerlein, I., Stenner-Liewen, F., Liewen, H., Kitada, S., Krajewska, M., Krajewski, S., Zapata, J. M., Monks, A., Scudiero, D. A., Bauknecht, T. & Reed, J. C. (2001). Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol 158, 1335-44.
58.	Ivanov, S., Liao, S. Y., Ivanova, A., Danilkovitch-Miagkova, A., Tarasova, N., Weirich, G., Merrill, M. J., Proescholdt, M. A., Oldfield, E. H., Lee, J., Zavada, J., Waheed, A., Sly, W., Lerman, M. I. & Stanbridge, E. J. (2001). Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158, 905-19.
59.	Grem, J. L., Danenberg, K. D., Behan, K., Parr, A., Young, L., Danenberg, P. V., Nguyen, D., Drake, J., Monks, A. & Allegra, C. J. (2001). Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res 7, 999-1009.
60.	Zapata, J. M., Krajewska, M., Krajewski, S., Kitada, S., Welsh, K., Monks, A., McCloskey, N., Gordon, J., Kipps, T. J., Gascoyne, R. D., Shabaik, A. & Reed, J. C. (2000). TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 165, 5084-96.
61.	Taverna, P., Liu, L., Hanson, A. J., Monks, A. & Gerson, S. L. (2000). Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 46, 507-16.
62.	Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A., Andreeff, M. & Reed, J. C. (2000). Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6, 1796-803.
63.	Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., Scudiero, D. A., Eisen, M. B., Sausville, E. A., Pommier, Y., Botstein, D., Brown, P. O. & Weinstein, J. N. (2000). A gene expression database for the molecular pharmacology of cancer. Nat Genet 24, 236-44.
64.	Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., Pergamenschikov, A., Lee, J. C., Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D. & Brown, P. O. (2000). Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24, 227-35.
65.	Fong, W. G., Liston, P., Rajcan-Separovic, E., St Jean, M., Craig, C. & Korneluk, R. G. (2000). Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 70, 113-22.
66.	Amundson, S. A., Myers, T. G., Scudiero, D., Kitada, S., Reed, J. C. & Fornace, A. J., Jr. (2000). An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 60, 6101-10.
67.	Kubo, A., Nakagawa, K., Varma, R. K., Conrad, N. K., Cheng, J. Q., Lee, W. C., Testa, J. R., Johnson, B. E., Kaye, F. J. & Kelley, M. J. (1999). The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res 5, 4279-86.
68.	Duan, Z., Feller, A. J., Toh, H. C., Makastorsis, T. & Seiden, M. V. (1999). TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229, 75-81.
69.	Chandler, L. A., Sosnowski, B. A., Greenlees, L., Aukerman, S. L., Baird, A. & Pierce, G. F. (1999). Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer 81, 451-8.
70.	Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. & Reed, J. C. (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58, 5315-20.
71.	Takayama, S., Krajewski, S., Krajewska, M., Kitada, S., Zapata, J. M., Kochel, K., Knee, D., Scudiero, D., Tudor, G., Miller, G. J., Miyashita, T., Yamada, M. & Reed, J. C. (1998). Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res 58, 3116-31.
72.	Kitada, S., Krajewska, M., Zhang, X., Scudiero, D., Zapata, J. M., Wang, H. G., Shabaik, A., Tudor, G., Krajewski, S., Myers, T. G., Johnson, G. S., Sausville, E. A. & Reed, J. C. (1998). Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 152, 51-61.
73.	Alvarez, M., Robey, R., Sandor, V., Nishiyama, K., Matsumoto, Y., Paull, K., Bates, S. & Fojo, T. (1998). Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. Mol Pharmacol 54, 802-14.
74.	Wosikowski, K., Schuurhuis, D., Johnson, K., Paull, K. D., Myers, T. G., Weinstein, J. N. & Bates, S. E. (1997). Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89, 1505-15.
75.	Woo, E. S., Monks, A., Watkins, S. C., Wang, A. S. & Lazo, J. S. (1997). Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel. Cancer Chemother Pharmacol 41, 61-8.
76.	Sreerama, L. & Sladek, N. E. (1997). Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Adv Exp Med Biol 414, 81-94.
77.	O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr. & Kohn, K. W. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57, 4285-300.
78.	Myers, T. G., Anderson, N. L., Waltham, M., Li, G., Buolamwini, J. K., Scudiero, D. A., Paull, K. D., Sausville, E. A. & Weinstein, J. N. (1997). A protein expression database for the molecular pharmacology of cancer. Electrophoresis 18, 647-53.
79.	Moscow, J. A., Connolly, T., Myers, T. G., Cheng, C. C., Paull, K. & Cowan, K. H. (1997). Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Int J Cancer 72, 184-90.
80.	Laurencot, C. M., Scheffer, G. L., Scheper, R. J. & Shoemaker, R. H. (1997). Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 72, 1021-6.
81.	Freije, J. M., Lawrence, J. A., Hollingshead, M. G., De la Rosa, A., Narayanan, V., Grever, M., Sausville, E. A., Paull, K. & Steeg, P. S. (1997). Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nat Med 3, 395-401.
82.	Tew, K. D., Monks, A., Barone, L., Rosser, D., Akerman, G., Montali, J. A., Wheatley, J. B. & Schmidt, D. E., Jr. (1996). Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 50, 149-59.
83.	Koo, H. M., Monks, A., Mikheev, A., Rubinstein, L. V., Gray-Goodrich, M., McWilliams, M. J., Alvord, W. G., Oie, H. K., Gazdar, A. F., Paull, K. D., Zarbl, H. & Vande Woude, G. F. (1996). Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 56, 5211-6.
84.	Izquierdo, M. A., Shoemaker, R. H., Flens, M. J., Scheffer, G. L., Wu, L., Prather, T. R. & Scheper, R. J. (1996). Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65, 230-7.
85.	Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R. & Lewis, A. D. (1996). Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88, 259-69.
86.	Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J. S., Weinstein, J., Grever, M., Bates, S. & Fojo, T. (1995). Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95, 2205-14.
87.	Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T. & Bates, S. E. (1994). Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46, 627-38.
88.	Budde, R. J., Ke, S. & Levin, V. A. (1994). Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 14, 171-5.
89.	Wu, L., Smythe, A. M., Stinson, S. F., Mullendore, L. A., Monks, A., Scudiero, D. A., Paull, K. D., Koutsoukos, A. D., Rubinstein, L. V., Boyd, M. R. & et al. (1992). Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52, 3029-34.
90.	Stinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H. H., Mullendore, L. A., Pittman, A. F., Kenney, S., Keller, J. & Boyd, M. R. (1992). Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 12, 1035-53.